MA27025A1 - Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabete - Google Patents
Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabeteInfo
- Publication number
- MA27025A1 MA27025A1 MA27399A MA27399A MA27025A1 MA 27025 A1 MA27025 A1 MA 27025A1 MA 27399 A MA27399 A MA 27399A MA 27399 A MA27399 A MA 27399A MA 27025 A1 MA27025 A1 MA 27025A1
- Authority
- MA
- Morocco
- Prior art keywords
- ppar
- diabetes
- alpha
- treatment
- carboxylic acid
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 150000007978 oxazole derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111745 | 2001-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27025A1 true MA27025A1 (fr) | 2004-12-20 |
Family
ID=8177436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27399A MA27025A1 (fr) | 2001-05-15 | 2003-11-14 | Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabete |
Country Status (38)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| KR100545507B1 (ko) * | 2000-05-26 | 2006-01-24 | 니뽄 신야쿠 가부시키가이샤 | 복소환 유도체 |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| PL208074B1 (pl) * | 2001-05-15 | 2011-03-31 | Hoffmann La Roche | Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| JP2005504043A (ja) * | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| JP2005528346A (ja) | 2002-02-25 | 2005-09-22 | イーライ・リリー・アンド・カンパニー | ペルオキシソーム増殖因子活性化受容体調節物質 |
| DK1537091T3 (da) * | 2002-08-30 | 2010-11-08 | Hoffmann La Roche | Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister |
| TWI343915B (en) | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
| AU2003302111A1 (en) * | 2002-11-15 | 2004-06-15 | Cadila Healthcare Limited | Substituted aralkyl derivatives |
| DE60323130D1 (de) * | 2002-11-25 | 2008-10-02 | Hoffmann La Roche | Indolderivaten |
| US7268157B2 (en) * | 2002-11-26 | 2007-09-11 | Shenzhen Chipscreen Biosciences, Ltd. | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
| FR2849849B1 (fr) * | 2003-01-13 | 2006-08-04 | Merck Sante Sas | Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7262303B2 (en) | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| JP2007509998A (ja) | 2003-11-05 | 2007-04-19 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐｐａｒ活性化剤としてのベンズ環付加された化合物 |
| KR20080042188A (ko) * | 2003-11-05 | 2008-05-14 | 에프. 호프만-라 로슈 아게 | Ｐｐａｒ 작용제로서 페닐 유도체 |
| WO2005056536A1 (en) * | 2003-12-10 | 2005-06-23 | Ranbaxy Laboratories Limited | Antidiabetic agents which exhibit activity against ppar |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| CA2564563C (en) | 2004-05-03 | 2011-07-05 | F. Hoffmann-La Roche Ag | Indolyl derivatives as liver-x-receptor modulators |
| CN100344618C (zh) * | 2004-05-24 | 2007-10-24 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物 |
| CN100436430C (zh) * | 2004-05-24 | 2008-11-26 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物 |
| WO2006108491A1 (en) * | 2005-04-11 | 2006-10-19 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Improved process for preparing oxazole nitriles |
| US20060241073A1 (en) * | 2005-04-20 | 2006-10-26 | Wanders Ronaldus J A | Means and methods for counteracting fatty acid accumulation |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| KR100847780B1 (ko) * | 2006-10-26 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제 |
| GB2460784A (en) * | 2007-03-07 | 2009-12-16 | Dong A Pharmtech Co Ltd | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition |
| PT2100604E (pt) * | 2008-03-10 | 2012-07-24 | Nestec Sa | Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas |
| AU2009246626A1 (en) * | 2008-05-15 | 2009-11-19 | Merck Sharp & Dohme Corp. | Oxazolobenzimidazole derivatives |
| KR101285520B1 (ko) | 2008-12-23 | 2013-07-17 | 에프. 호프만-라 로슈 아게 | 만성 질병을 가진 환자의 진단 또는 치료 지원을 위한 구조화된 테스팅 방법 및 그 디바이스 |
| AU2010206249B2 (en) * | 2009-01-23 | 2015-07-09 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising aleglitazar |
| CN101805337B (zh) * | 2009-02-13 | 2012-05-23 | 天津药物研究院 | 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途 |
| US8450496B2 (en) | 2009-03-24 | 2013-05-28 | Hoffman-La Roche Inc. | Process for the preparation of propionic acid derivatives |
| NZ600273A (en) | 2009-12-07 | 2014-03-28 | Hoffmann La Roche | Process for the preparation of propionic acid derivatives |
| CN102351852B (zh) * | 2011-08-23 | 2014-06-18 | 上海交通大学 | 苯并呋喃类化合物及其制备方法、用途 |
| WO2013181384A1 (en) | 2012-05-31 | 2013-12-05 | Ratiopharm Gmbh | Solid state forms of aleglitazar sodium |
| CN104619689B (zh) * | 2012-09-12 | 2017-08-08 | 霍夫曼-拉罗奇有限公司 | (S)‑2‑甲氧基‑3‑{4‑[2‑(5‑甲基‑2‑苯基‑噁唑‑4‑基)‑乙氧基]‑苯并[b]噻吩‑7‑基}‑丙酸的固体形式及其盐的固体形式 |
| CN109588042A (zh) | 2015-11-18 | 2019-04-05 | 豪夫迈·罗氏有限公司 | 用于治疗糖尿病肾病的阿格列扎 |
| WO2018002215A1 (en) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
| WO2020156683A1 (en) | 2019-02-01 | 2020-08-06 | F. Hoffmann-La Roche Ag | Aleglitazar for use in the treatment or prevention of major adverse cardiac events |
| WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
| JP2024532807A (ja) * | 2021-08-13 | 2024-09-10 | アレバンド ファーマシューティカルズ（ホンコン）リミテッド | 重水素化化合物 |
| JP2025538159A (ja) | 2022-11-08 | 2025-11-26 | ジェンフィット | 肝不全の治療において使用するためのｐｐａｒ－アルファ／ガンマアゴニスト |
| CN118480034B (zh) * | 2023-02-13 | 2025-02-11 | 礼邦医药(香港)有限公司 | 氘代化合物的晶型或盐 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011326A (en) | 1975-07-29 | 1977-03-08 | Merck & Co., Inc. | 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents |
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| RU2032677C1 (ru) * | 1992-05-05 | 1995-04-10 | Бристоль-Мейерз Сквибб Компани | Производные оксазола |
| EP0648212B1 (en) | 1992-07-03 | 2001-10-24 | Smithkline Beecham Plc | Benzoxazole and benzothiazole derivatives as pharmaceutical |
| GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
| DE4317320A1 (de) | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
| GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| ZA9711051B (en) | 1996-12-10 | 1999-06-09 | Bristol Myers Squibb Co | Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents |
| DE19711616A1 (de) * | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Verbessertes Verfahren zur Herstellung von Thiazolidindionen |
| US6121397A (en) | 1997-07-14 | 2000-09-19 | Xerox Corporation | Polymerization processes using oligomeric compound, monomer and surfactant |
| HN1998000118A (es) | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| ES2200248T3 (es) | 1997-09-19 | 2004-03-01 | Ssp Co., Ltd. | Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen. |
| WO1999008501A2 (en) | 1998-04-23 | 1999-02-25 | Dr. Reddy's Research Foundation | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| EP1078923B1 (en) | 1999-08-02 | 2006-03-08 | F. Hoffmann-La Roche Ag | Process for the preparation of benzothiophene derivatives |
| EA200300286A1 (ru) * | 2000-08-23 | 2003-08-28 | Эли Лилли Энд Компани | Агонисты активируемых пероксисомальным пролифератором рецепторов |
| PL208074B1 (pl) * | 2001-05-15 | 2011-03-31 | Hoffmann La Roche | Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu |
-
2002
- 2002-05-06 PL PL367087A patent/PL208074B1/pl unknown
- 2002-05-06 EP EP02742955A patent/EP1392295B1/en not_active Expired - Lifetime
- 2002-05-06 WO PCT/EP2002/004962 patent/WO2002092084A1/en not_active Ceased
- 2002-05-06 IL IL15858902A patent/IL158589A0/xx unknown
- 2002-05-06 HR HR20030889A patent/HRP20030889B1/xx not_active IP Right Cessation
- 2002-05-06 DK DK02742955T patent/DK1392295T3/da active
- 2002-05-06 ME MEP-2008-775A patent/ME01310B/me unknown
- 2002-05-06 SI SI200230340T patent/SI1392295T1/sl unknown
- 2002-05-06 JP JP2002589001A patent/JP4330883B2/ja not_active Expired - Fee Related
- 2002-05-06 HU HU0400992A patent/HU230224B1/hu not_active IP Right Cessation
- 2002-05-06 ES ES02742955T patent/ES2264482T3/es not_active Expired - Lifetime
- 2002-05-06 SK SK1385-2003A patent/SK287842B6/sk not_active IP Right Cessation
- 2002-05-06 PT PT02742955T patent/PT1392295E/pt unknown
- 2002-05-06 RU RU2003134150/04A patent/RU2278859C2/ru not_active IP Right Cessation
- 2002-05-06 DE DE60211891T patent/DE60211891T2/de not_active Expired - Lifetime
- 2002-05-06 KR KR1020037014816A patent/KR100654516B1/ko not_active Expired - Fee Related
- 2002-05-06 AT AT02742955T patent/ATE327753T1/de active
- 2002-05-06 MX MXPA03010435A patent/MXPA03010435A/es active IP Right Grant
- 2002-05-06 CN CNB028100964A patent/CN100356917C/zh not_active Expired - Fee Related
- 2002-05-06 BR BRPI0209821A patent/BRPI0209821B1/pt not_active IP Right Cessation
- 2002-05-06 AU AU2002342244A patent/AU2002342244B2/en not_active Ceased
- 2002-05-06 NZ NZ529033A patent/NZ529033A/en not_active IP Right Cessation
- 2002-05-06 CA CA002445145A patent/CA2445145C/en not_active Expired - Fee Related
- 2002-05-06 CZ CZ20033037A patent/CZ20033037A3/cs unknown
- 2002-05-09 US US10/142,567 patent/US6642389B2/en not_active Expired - Lifetime
- 2002-05-13 JO JO200242A patent/JO2282B1/en active
- 2002-05-13 MY MYPI20021726A patent/MY136761A/en unknown
- 2002-05-13 AR ARP020101739A patent/AR035892A1/es active IP Right Grant
- 2002-05-14 PA PA20028544901A patent/PA8544901A1/es unknown
- 2002-05-14 GT GT200200085A patent/GT200200085A/es unknown
- 2002-05-14 PE PE2002000399A patent/PE20021152A1/es active IP Right Grant
- 2002-05-14 EG EG2002050495A patent/EG25755A/xx active
-
2003
- 2003-10-23 IL IL158589A patent/IL158589A/en unknown
- 2003-10-31 ZA ZA2003/08538A patent/ZA200308538B/en unknown
- 2003-11-13 EC EC2003004848A patent/ECSP034848A/es unknown
- 2003-11-14 BG BG108362A patent/BG66316B1/bg unknown
- 2003-11-14 MA MA27399A patent/MA27025A1/fr unknown
- 2003-11-14 NO NO20035086A patent/NO333833B1/no not_active IP Right Cessation
-
2006
- 2006-08-22 CY CY20061101162T patent/CY1105160T1/el unknown
-
2009
- 2009-02-10 JP JP2009028181A patent/JP2009138011A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27025A1 (fr) | Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabete | |
| RU92016445A (ru) | Применение амидов изоксазол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты | |
| EP0706373A4 (en) | TAXOL ENCLOSED IN LIPOSOMES AND METHOD OF USE | |
| FI933946A7 (fi) | Hypoglykeemisinä aineina ja Alzheimerin taudin hoidossa käyttökelpoisia yhdisteitä | |
| NO932983L (no) | Fettsyrebehandling | |
| IT1224795B (it) | Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento | |
| FR2702148B1 (fr) | Application d'anticonvulsivants dans le traitement du neuro-sida. | |
| DE69312579D1 (de) | Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit | |
| ES2155517T3 (es) | Derivados del acido n-acetil-neuraminico y procedimientos para su preparacion. | |
| DE69822971D1 (de) | Fluorsubstituierte 4-Alkylenbenzosäure, sowie Derivate, nematische Flüssigkristallzusammensetzung enthaltend Cyabophenylbenzosäureester-Derivate und Flüssigkristallanzeigesystem, das diese verwendet | |
| DE69434356D1 (de) | Inclusion-Komplex von Beta-Cyclodextrin mit Diclofenac | |
| ITRM910002A0 (it) | Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento. | |
| ATE149310T1 (de) | Methode und lösung zur bestimmung der wirkungsdauer einer auf die hornhaut aufgebrachten substanz | |
| FI892061A0 (fi) | Menetelmä, jonka avulla voidaan valmistaa ferrikloridia lähtemällä ferrokloridista | |
| MA22195A1 (fr) | Procede de preparation de derives de l'acide benzoique destines au traitement des maladies associees aux lencotrienes | |
| ATE345123T1 (de) | Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten | |
| FI954138A7 (fi) | Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä | |
| MA22196A1 (fr) | Procede de preparation de derives de l'acide benzoique destines au traitement des maladies associees aux leucotrienes | |
| EP0305277A3 (fr) | Application de l'amino-2 trifluoro-méthoxy-6 benzothiazole pour obtenir un médicament destiné au traitement des troubles du sommeil et de la dépression | |
| EP0305276A3 (fr) | Application de l'amino-2 trifluorométhoxy-6 benzothiazole pour obtenir un médicament destiné au traitement de la schizophrénie | |
| MA22197A1 (fr) | Procede de preparation de derives de l'acide benzoique destines au traitement des maladies associees aux leucotrienes | |
| FI943236L (fi) | Tristyryylifenolipolyalkoksifosfaattijohdannaisten nestemäinen konsentroitu koostumus käytettäväksi erityisesti maataloudessa | |
| FR2702149B1 (fr) | Application de la lamotrigine dans le traitement du neuro-sida. | |
| ES2191825T3 (es) | Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia. | |
| SE501325E (sv) | Förfarande för klorfri blekning av massa, varvid massan surgöres med ättiksyra vid behandlingen med komplexbildare |